[CAS NO. 1303993-73-8] CHPG sodium salt
PRODUCTS SPECIFICATIONS [1303993-73-8]
DESCRIPTION [1303993-73-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 223.59 |
| Molecular Formula | C8H7ClNNaO3 |
| SMILES | O=C(O[Na])C(N)C1=CC(O)=CC=C1Cl |
Summary
CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO 2 -induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells [1] . CHPG sodium salt protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways. [2] .
IC50 & Target
|
mGlu 5 |
NF-κB |
ERK |
In Vitro
CHPG sodium salt (10-500 µM; 24 hours) significantly increases the cell viability and decreases the LDH release after SO
2
derivatives treatment
[1]
.
CHPG sodium salt (0.5 mM; 30 mins ) protects BV2 cells against SO
2
-induced apoptosis
[1]
.
CHPG sodium salt (0.5 mM; 30 mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | BV2 microglial cells |
| Concentration: | 10, 50, 100 and 500 µM |
| Incubation Time: | 24 hours |
| Result: | Increased the cell viability. |
Apoptosis Analysis [1]
| Cell Line: | BV2 microglial cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 30 mins |
| Result: | Protected BV2 cells against SO 2 -induced apoptosis. |
Western Blot Analysis [1]
| Cell Line: | BV2 microglial cells |
| Concentration: | 0.5 mM |
| Incubation Time: | 30 mins |
| Result: | Increased the expression of TSG-6 in both mRNA and protein levels. |
In Vivo
CHPG sodium salt (injection; 250 nM; for 7 days) reduces significantly cerebral lesion volume [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Adult Sprague-Dawley male rats weighing 280-320 g [2] |
| Dosage: | 250 nM |
| Administration: | Injection; for 7 days |
| Result: | Reduced significantly cerebral lesion volume. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL ( 447.25 mM ; Need ultrasonic)
H 2 O : 6.67 mg/mL ( 29.83 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.4725 mL | 22.3624 mL | 44.7247 mL |
| 5 mM | 0.8945 mL | 4.4725 mL | 8.9449 mL |
| 10 mM | 0.4472 mL | 2.2362 mL | 4.4725 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 5 mg/mL (22.36 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (11.18 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (11.18 mM); Clear solution
References
- [1] Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO -induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Neurochem Int. 2015 Jun-Jul;85-86:46-52.
- [2] Chen T, et al. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med. 2012 Apr;29(4):630-6.